Dr. Sennewald Medizintechnik was founded with the aim of discovering innovative and beneficial cancer therapies and we have since amassed over 35 years of experience in regional and superficial hyperthermia.
Our aim is to help improve the range of products on offer, to support the growth of this proven technology and so increase the survival rate among cancer patients.
The hyperthermia systems of Pyrexar Medical were designed for maximum efficacy combined with minimum risk for greater patient comfort and are installed in oncology departments, research organizations and leading universities throughout Europe.
Our unrivaled links to the scientific community have led to the acceptance of hyperthermia, the development of dedicated software, the reimbursement of hyperthermia and its use in the treatment of children. Strategic partnerships with medical centers have resulted in phase III clinical studies demonstrating that Pyrexar systems offer a significant increase in cancer response rates.
